Barclays
AGIO icon

Barclays’s Agios Pharmaceuticals AGIO Stock Holding History

Barclays’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-52,200
Closed -$1.42M – 5010
2025
Q4 		$1.42M Buy
+52,200
New +$1.83M ﹤0.01% 3184
2024
Q4 		– Sell
-32,200
Closed -$1.43M – 5251
2024
Q3 		$1.43M Hold
32,200
– – ﹤0.01% 3116
2024
Q2 		$1.39M Buy
32,200
+2,200
+7% +$79.4K ﹤0.01% 2391
2024
Q1 		$877K Sell
30,000
-30,000
-50% -$803K ﹤0.01% 3222
2023
Q4 		$1.34M Buy
+60,000
New +$1.34M ﹤0.01% 3226
2019
Q3 		– Sell
-300
Closed -$15K – 6667
2019
Q2 		$15K Hold
300
– – ﹤0.01% 6471
2019
Q1 		$20K Sell
300
-147,500
-100% -$8.59M ﹤0.01% 6352
2018
Q4 		$6.82M Buy
+147,800
New +$9.12M 0.01% 1393
2018
Q3 		– Sell
-27,000
Closed -$2.27M – 7085
2018
Q2 		$2.27M Hold
27,000
– – ﹤0.01% 2465
2018
Q1 		$2.21M Buy
+27,000
New +$2.09M ﹤0.01% 2366
2015
Q1 		– Sell
-25,800
Closed -$2.89M – 7047
2014
Q4 		$2.89M Buy
+25,800
New +$2.3M ﹤0.01% 2192

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Barclays's AGIO Position: Q1 2026 in Review

Barclays reduced its Agios Pharmaceuticals (AGIO) stake by 84% in Q1 2026, selling an estimated $7.6M and leaving 52,438 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2422.

Barclays first reported a position in AGIO in Q3 2013 and has held it in 51 quarters since. The position peaked at $8.72M in Q4 2025. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Barclays held 52,438 shares of Agios Pharmaceuticals worth $1.77M as of Q1 2026.
  • Barclays sold 267,914 Agios Pharmaceuticals shares in Q1 2026, an estimated $7.6M.
  • Agios Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2422 holding.
  • Barclays first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
  • Barclays's Agios Pharmaceuticals position peaked at $8.72M in Q4 2025.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.